Amphastar Pharmaceuticals, Inc. Other Comprehensive Income (Loss), before Tax
Amphastar Pharmaceuticals, Inc. (AMPH) reported Other Comprehensive Income (Loss), before Tax of -$2.99 million for the 3-month period ending 2015-03-31, per its 10-Q filed 2015-05-14.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossBeforeTax · last filed 2015-05-14
- Amphastar Pharmaceuticals, Inc. other comprehensive income (loss), before tax for the quarter ending 2015-03-31 was -$2.99M.
- Amphastar Pharmaceuticals, Inc. other comprehensive income (loss), before tax for the quarter ending 2014-12-31 was $149.00K.
- Amphastar Pharmaceuticals, Inc. other comprehensive income (loss), before tax for the quarter ending 2014-09-30 was -$1.53M.
- Amphastar Pharmaceuticals, Inc. other comprehensive income (loss), before tax for the quarter ending 2014-06-30 was -$268.00K.
- Amphastar Pharmaceuticals, Inc. other comprehensive income (loss), before tax for fiscal 2014 was -$1.65M.
| Period end | Other Comprehensive Income (Loss), before Tax 3 month | Other Comprehensive Income (Loss), before Tax 6 month | Other Comprehensive Income (Loss), before Tax 9 month | Other Comprehensive Income (Loss), before Tax 12 month |
|---|---|---|---|---|
| 2015-03-31 | -$2.99M 10-Q · filed 2015-05-14 | -$2.84M derived: sum of 2 quarters · filed 2015-05-14 | -$4.38M derived: sum of 3 quarters · filed 2015-05-14 | -$4.65M derived: sum of 4 quarters · filed 2015-05-14 |
| 2014-12-31 | $149.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-26 | -$1.39M derived: sum of 2 quarters · filed 2015-03-26 | -$1.65M derived: sum of 3 quarters · filed 2015-03-26 | -$1.65M 10-K · filed 2015-03-26 |
| 2014-09-30 | -$1.53M 10-Q · filed 2014-11-13 | -$1.80M derived: sum of 2 quarters · filed 2014-11-13 | -$1.80M 10-Q · filed 2014-11-13 | |
| 2014-06-30 | -$268.00K 10-Q · filed 2014-08-13 | -$268.00K 10-Q · filed 2014-08-13 | ||
| 2014-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |